Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA reports news on its AI-driven precision medicine software business and the adoption of the SOPHiA DDM Platform by hospitals, laboratories, and biopharma institutions. Company updates commonly cover financial results, analysis volumes, customer additions, U.S. market expansion, and applications that analyze genomic and multimodal data for cancer and rare disorders.
Recurring developments include health-system collaborations, next-generation sequencing workflows for blood cancers and solid tumors, Liquid Biopsy and Enhanced Exomes applications, and management commentary on platform demand, gross margin, operating leverage, and biopharma activity.
SOPHiA GENETICS (Nasdaq: SOPH) will host a joint symposium with GE Healthcare on December 1, 2021, at the RSNA Annual Meeting in Chicago. The event, focused on advancing data-driven medicine, will explore multimodal digital health data integration using AI-powered analytics. This follows a recent Master Alliance Agreement between the two companies, aiming to enhance collaboration in healthcare solutions, particularly in digital oncology and radiogenomics. The partnership is expected to accelerate the adoption of SOPHiA's platform, enhancing healthcare delivery for cancer patients worldwide.
Balderton Capital has launched its largest-ever fund of $600m to support early-stage startups, complementing its Growth fund raised earlier this year. The firm is now deploying over $1.2bn across Europe, leveraging its extensive investment team of 25 experts. Balderton has made close to 300 investments, including 20 new startups in various sectors. Its portfolio companies have raised over $6bn in follow-on funding this year, highlighting a successful track record with 13 companies reaching unicorn status.
SOPHiA GENETICS (Nasdaq: SOPH) reported a robust 45% year-over-year revenue growth for Q3 2021, reaching $10.4 million. The company executed a Master Alliance Agreement with GE Healthcare to enhance oncology initiatives, expanding its market presence. Total recurring platform customers rose to 375, with a net dollar retention rate of 137%. Despite a net loss of $21.2 million or 35 cents per share, the company anticipates full-year revenue exceeding $40 million, indicating at least 41% growth for 2021.
SOPHiA GENETICS SA (Nasdaq: SOPH) has enhanced its SOPHiA DDM Universal Whole Exome platform with the integration of Agilent's SureSelect Human All Exon v8. This new bioinformatic workflow streamlines analysis from sample to variant report, supporting both germline and cancer applications. Key features include reduced turnaround time, multiple variant detection, tailored analytics for Agilent data, and a comprehensive gene coverage. The solution aims to accelerate research in rare and inherited diseases, making data-driven medicine more accessible.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in several upcoming investor conferences, including the Credit Suisse 30th Annual Healthcare Conference on November 11, the Piper Sandler 33rd Annual Healthcare Conference starting November 22, and the Evercore ISI HealthCONx Conference on November 30. Investors can access live and archived presentations through the company's Investors section on their website. SOPHiA GENETICS focuses on data-driven medicine, utilizing its cloud-based SOPHiA DDM™ Platform in over 780 institutions worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) announced it will report Q3 financial results on November 10, 2021, before the market opens. Management will host a webcast at 8:30 a.m. ET to discuss results, business advancements, and future outlook. The SOPHiA DDM™ Platform, their cloud-based SaaS solution, is utilized by over 780 institutions globally, aiming to set data-driven medicine as a standard. The live audio will be available on the company’s Investors section of the website, with an archived replay afterwards.
SOPHiA GENETICS (Nasdaq: SOPH) has launched the SOPHiA Clinical Exome Solution v3, which enhances probe design and detection capabilities for investigating Mendelian diseases. This application combines a capture-based target enrichment kit with the SOPHiA DDM™ platform, achieving over 90% analytical sensitivity for CNV detection. Enhanced probe design allows for improved detection of rare disorders across the mitochondrial genome and 280 known disorder-causing genomic locations. This innovation aims to streamline data analysis and improve institutional resource efficiency.
SOPHiA GENETICS (NASDAQ: SOPH) reported Q2 2021 revenue of $10.2 million, a 72% increase Year-over-Year (YoY). The customer base grew to 780. The company raised approximately $217 million from its IPO and $20 million from a private placement. Q2 gross profit was $6.2 million, with a margin of 61%, down from 67% in Q2 2020. Operating expenses rose to $22.2 million, leading to a net loss of $18.4 million. For 2021, revenue guidance exceeds $39 million, projecting over 37% growth.
SOPHiA GENETICS (Nasdaq: SOPH) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. The presentation is scheduled for 9:30 a.m. Eastern Time/3:30 p.m. Central European Time and will be accessible via a live and archived webcast on the company’s website.
The company is a leader in data-driven medicine and offers the SOPHiA DDM™ Platform, which supports over 780 institutions globally in analyzing complex data sets for healthcare and life sciences.
SOPHiA GENETICS (Nasdaq: SOPH) will release its second quarter 2021 financial results on September 9, 2021, before market open. The management will host a conference call at 8:30 a.m. ET to discuss these results, alongside business developments and future outlook. The company focuses on data-driven medicine and operates the SOPHiA DDM™ Platform, utilized by over 780 institutions globally. A live webcast of the call will be accessible in the 'Investors' section of their website, with an archived replay available post-event.